Dynavax Technologies 株価情報 (NASDAQ: DVAX)

最新ニュース Dynavax Technologies (NASDAQ:DVAX) 株価情報

Dynavax Technologies

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies Corp

Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reflecting updated views and recent competitive <a target="_blank" href="https://www.benzinga.com/quote/DVAX" rel="noreferrer noopener">dynamics for vaccines</a>.
Goldman Sachs analyst Paul Choi has downgraded Dynavax to Sell from Neutral and cut the <a target="_blank" href="https://www.benzinga.com/quote/DVAX/analyst-ratings" rel="noreferrer noopener">price target from $15 to $12</a>. He notes growing competition in the shingles vaccine market, which could reduce the potential value of the Z-1018 program and add uncertainty to its long-term revenue.
Potential convenience improvements come from GSK Plc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Shingrix with the company's pre-filled syringes, which have been accepted for review by <a target="_blank" href="https://www.benzinga.com/25/02/43492835/gsk-launches-share-buyback-of-around-25-billion-after-better-than-expected-q4-earnings-raises-long-term-annual-sales-forecast-to-over-50-billion" rel="noreferrer noopener">both the FDA and EMA</a> (U.S. decision expected by 20 June).
Dynavax is conducting a Phase 1/2 trial to evaluate the safety, tolerability, and immunogenicity of Z-1018 compared to GSK's Shingrix in 441 healthy adults aged 50 to 69.
Choi also points to uncertain demand for repeat hepatitis B vaccinations in the 2030s, which may impact Heplisav-B's outlook beyond its peak sales. Despite its market share gains, questions remain about the FDA and ACIP's regulatory stance on vaccines in the U.S.
Last month,&nbsp;Dynavax announced preliminary HEPLISAV-B net product revenue of&nbsp;$268 million&nbsp;for 2024, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42945098/dynavax-announces-preliminary-unaudited-fourth-quarter-and-full-year-2024-financial-highlights" rel="noreferrer noopener">up 26% year-over-year</a>.
HEPLISAV-B net product revenue reached&nbsp;$71 million&nbsp;for the fourth quarter of 2024, up 39%.
In May 2024, the FDA issued a Complete Response Letter stating that the application did not provide sufficient data to fully evaluate the effectiveness or safety of a four-dose <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38818397/fda-declines-to-approve-expanded-use-of-dynavaxs-hepatitis-b-vaccine-in-hemodialysis-patients" rel="noreferrer noopener">regimen of HEPLISAV-B</a>.&nbsp;
Dynavax is expected to report fourth-quarter earnings <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43548293/dynavax-to-report-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-" rel="noreferrer noopener">on 20 February</a>.
As per data from Benzinga Pro, analysts estimate Q4 adjusted EPS of $0.04, with sales of $72.92 million.
Analysts forecast 2024 sales of $278.13 million and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">adjusted EPS of $0.12</a>.
Price Action: DVAX stock is down 4.13% at $12.66 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43629227/nano-cap-lipella-pharmaceuticals-stock-jumps-on-positive-trial-data-in-patients-with-sore-mouth-membranes" target="_blank" rel="noreferrer noopener">Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes</a></li>
</ul>

Analyst Color

Biotech

News

Downgrades

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

DVAX

Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty

WIIM

Dynavax shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Oppenheimer analyst Tyler Batory downgraded the rating for Playa Hotels &amp; Resorts N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLYA#NASDAQ">PLYA</a>) from Outperform to Perform. Playa Hotels shares closed at $13.24 on Monday. <a href="https://www.benzinga.com/quote/PLYA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Ameet Thakkar downgraded Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) from Outperform to Market Perform and lowered the price target from $22 to $10. Fluence Energy shares closed at $13.07 on Monday. <a href="https://www.benzinga.com/quote/FLNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Paul Choi downgraded the rating for Dynavax Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) from Neutral to Sell and slashed the price target from $15 to $12. Dynavax shares closed at $13.20 on Monday. <a href="https://www.benzinga.com/quote/DVAX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Christopher Raymond downgraded Q32 Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) from Overweight to Neutral and cut the price target from $20 to $4. Q32 Bio shares closed at $3.18 on Monday. <a href="https://www.benzinga.com/quote/QTTB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Matt Summerville downgraded the rating for Columbus McKinnon Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCO#NASDAQ">CMCO</a>) from Buy to Neutral and announced a $35 price target. Columbus McKinnon shares closed at $35.48 on Monday. <a href="https://www.benzinga.com/quote/CMCO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CMCO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91-1024x593.png" alt="" class="wp-image-776431" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91.png 1108w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43592071/top-3-tech-stocks-that-may-jump-this-month">Top 3 Tech Stocks That May Jump This Month</a></li>
</ul>
Photo: Shutterstock

Pre-Market Outlook

Markets

CMCO

FLNC

PLYA

QTTB

This Columbus McKinnon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Goldman Sachs analyst Paul Choi downgrades Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) from Neutral to Sell and lowers the price target from $15 to $12.

Goldman Sachs Downgrades Dynavax Technologies to Sell, Lowers Price Target to $12

HC Wainwright &amp; Co. analyst Edward White maintains Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Buy and raises the price target from $29 to $31.

HC Wainwright & Co. Maintains Buy on Dynavax Technologies, Raises Price Target to $31

Guidance

Dynavax Prelim. 2024 HEPLISAV-B Net Product Revenue Grew 26% YoY To $268M

Buybacks

Dynavax Announces $100M Accelerated Share Repurchase Program Under Agreement With Goldman Sachs

Dynavax Technologies shares are trading higher after the company reported better-than-expected Q3 EPS results and launched a $200 million share buyback program. HC Wainwright & Co. reiterated a Buy rating on the stock.

HC Wainwright &amp; Co. analyst Edward White reiterates Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Buy and maintains $29 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $29 Price Target

Dynavax Launches $200M Share Buyback Program With Board Approval; Repurchases Expected To Be Completed Within One Year

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.11 by 9.09 percent. The company reported quarterly sales of $80.630 million which missed the analyst consensus estimate of $84.166 million by 4.20 percent. This is a 15.99 percent increase over sales of $69.514 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Dynavax Technologies Q3 2024 GAAP EPS $0.12 Beats $0.11 Estimate, Sales $80.630M Miss $84.166M Estimate

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) will release its quarterly earnings report on Thursday, 2024-11-07. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Dynavax Technologies to report an earnings per share (EPS) of $0.11.
The announcement from Dynavax Technologies is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.02, leading to a 6.97% increase in the share price the following trading session.
Here's a look at Dynavax Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.06</td>
<td>-0.02</td>
<td>-0.01</td>
<td>-0.01</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.08</td>
<td>-0.07</td>
<td>0</td>
<td>0.10</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.000000000000001%</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730919682_0.png" alt="eps graph" />
<h3>Performance of Dynavax Technologies Shares</h3>
Shares of Dynavax Technologies were trading at $12.01 as of November 05. Over the last 52-week period, shares are down 6.38%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on Dynavax Technologies</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Dynavax Technologies.
The consensus rating for Dynavax Technologies is Buy, based on 2 analyst ratings. With an average one-year price target of $22.0, there's a potential 83.18% upside.
<h3>Comparing Ratings with Competitors</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Myriad Genetics and Kiniksa Pharmaceuticals, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Neutral trajectory for Myriad Genetics, with an average 1-year price target of $32.75, indicating a potential 172.69% upside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Kiniksa Pharmaceuticals, with an average 1-year price target of $38.33, indicating a potential 219.15% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Myriad Genetics and Kiniksa Pharmaceuticals, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dynavax Technologies</td>
<td>Buy</td>
<td>22.48%</td>
<td>$61.81M</td>
<td>1.81%</td>
</tr>
<tr>
<td>Myriad Genetics</td>
<td>Neutral</td>
<td>15.26%</td>
<td>$147.10M</td>
<td>-4.89%</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals</td>
<td>Outperform</td>
<td>67.37%</td>
<td>$62.80M</td>
<td>-2.91%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Dynavax Technologies ranks highest in Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Dynavax Technologies is at the bottom compared to its peers.
<h3>Delving into Dynavax Technologies's Background</h3>
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
<h3>Breaking Down Dynavax Technologies's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Dynavax Technologies showcased positive performance, achieving a revenue growth rate of 22.48% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Dynavax Technologies's net margin is impressive, surpassing industry averages. With a net margin of 15.43%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Dynavax Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of 1.81%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Dynavax Technologies's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.14%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.39, Dynavax Technologies faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/DVAX/earnings">To track all earnings releases for Dynavax Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Dynavax Technologies's Upcoming Earnings

Dynavax Technologies Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>), a commercial-stage biopharmaceutical company developing and&nbsp;commercializing innovative vaccines, today announced that its Board of Directors has adopted a limited-duration stockholder rights plan, effective immediately (the "Rights Plan").
The Dynavax Board adopted the Rights Plan in response to the recent rapid accumulations of stock by Deep Track Capital, which recently disclosed in a Schedule 13D/A filing its ownership of 13.6% of the Company's outstanding common stock. The Rights Plan is intended to protect the investment of Dynavax stockholders during a period in which it believes shares of the Company do not reflect the inherent value of the business or its long-term growth potential. The Rights Plan should reduce the likelihood that any person or group gains control of Dynavax through open market accumulation without paying all stockholders an appropriate control premium or without providing the Board sufficient time to make informed judgments and take actions that are in the best interests of all stockholders.
The Rights Plan, which is similar to other plans adopted by publicly held companies, does not contain any dead-hand, slow-hand, no-hand or similar feature that limits the ability of a future Board to redeem the rights. The Rights Plan does not limit the Board's ability to engage in discussions or pursue transactions it believes are in the best interests of all stockholders.

Management

Dynavax Adopts Limited-Duration Stockholder Rights Plan, Effective Immediately

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $25.5, a high estimate of $29.00, and a low estimate of $15.00. This current average represents a 4.67% decrease from the previous average price target of $26.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1723132810_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Dynavax Technologies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dynavax Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dynavax Technologies compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Dynavax Technologies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Dynavax Technologies's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DVAX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dynavax Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Dynavax Technologies</h2>
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
<h3>Dynavax Technologies: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Dynavax Technologies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 22.48% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dynavax Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.43% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Dynavax Technologies's ROE excels beyond industry benchmarks, reaching 1.81%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Dynavax Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.14% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Dynavax Technologies's debt-to-equity ratio stands notably higher than the industry average, reaching 0.39. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Dynavax Technologies: Insights From 4 Financial Analysts

Goldman Sachs analyst Paul Choi maintains Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Neutral and lowers the price target from $20 to $15.

Goldman Sachs Maintains Neutral on Dynavax Technologies, Lowers Price Target to $15

Dynavax Reaffirms 2024 HEPLISAV-B Net Product Revenue Guidance Of $265M-$280M

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 33.33 percent. This is a 166.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $73.795 million which missed the analyst consensus estimate of $76.102 million by 3.03 percent. This is a 22.48 percent increase over sales of $60.249 million the same period last year.

Dynavax Technologies Q2 2024 GAAP EPS $0.08 Beats $0.06 Estimate, Sales $73.795M Miss $76.102M Estimate

Dynavax Reappoints Kelly MacDonald As CFO Effective August 1, 2024; Ryan Spencer Continues As CEO After Serving As Interim CFO During MacDonald's Maternity Leave; No Change In MacDonald's Compensation

Dynavax Technologies guides Q4 and FY topline figures

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Dynavax (DVAX – Research Report) today and set a price target of $29.00. The company...

Dynavax (DVAX) Receives a Buy from JMP Securities

Analyst Phil Nadeau of TD Cowen maintained a Buy rating on Dynavax (DVAX – Research Report), retaining the price target of $25.00. Phil Nadeau has ...

Strong Market Position and Growth Potential Drive Buy Rating for Dynavax

H.C. Wainwright analyst Edward White has reiterated their bullish stance on DVAX stock, giving a Buy rating yesterday. Edward White's rating is bas...

Dynavax's Strong Growth Potential Driven by Heplisav-B Sales and Strategic Market Positioning

H.C. Wainwright raised the firm's price target on Dynavax (DVAX) to $31 from $29 and keeps a Buy rating on the shares. The company's preliminary Q4...

Dynavax price target raised to $31 from $29 at H.C. Wainwright

Dynavax ( ($DVAX) ) has shared an announcement. Dynavax Technologies Corporation has appointed two new directors, Lauren Silvernail and Emilio Emin...

Dynavax Announces New Board Appointments and Adjustments

Dynavax Technologies: Time To Refocus On Former Cash Cow CpG1018

The latest announcement is out from Dynavax ( ($DVAX) ). On February 3, 2025, Justin Burgess announced his resignation from Dynavax Technologies Co...

Dynavax Announces Leadership Transition Following Resignation

Goldman Sachs downgraded Dynavax (DVAX) to Sell from Neutral with a price target of $12, down from $15. The evolving competitive landscape in shing...

Dynavax downgraded to Sell from Neutral at Goldman Sachs

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Comments

Dynavax Technologies

ニュース

最新ニュース Dynavax Technologies (NASDAQ:DVAX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル